Five big pharma deals in Humira market could save UK £300m
At least 80% of patients currently taking AbbVie’s blockbuster drug could be switched to “the best value biological medicine” within 12 months, according to the UK National Health Service.
Archives for November 30, 2018
Bayer to shed €600m factor VIII facility and 12,000 staff
Bayer looks to boost investor confidence by cutting away its animal health unit, selected consumer health brands and a number of jobs to focus on its life sciences businesses.
EU rules Avastin can be reimbursed for off-label use
The European Court of Justice has determined that Roche’s Avastin may be reimbursed for ARMD – despite Novartis and Bayer’s challenge.
Celltrion and Teva announce first Rituxan biosimilar approval in US
Celltrion and Teva have overcome regulatory hurdles to secure approval for Truxima in the US, a biosimilar to non-Hodgkin’s lymphoma treatment, Rituxan.